These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22154381)

  • 1. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome.
    Krause K; Feist E; Fiene M; Kallinich T; Maurer M
    J Allergy Clin Immunol; 2012 Mar; 129(3):848-50. PubMed ID: 22154381
    [No Abstract]   [Full Text] [Related]  

  • 2. Schnitzler syndrome: response to anakinra in two cases and a review of the literature.
    Schuster C; Kränke B; Aberer E; Arbab E; Sturm G; Aberer W
    Int J Dermatol; 2009 Nov; 48(11):1190-4. PubMed ID: 20064173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
    Betrains A; Staels F; Vanderschueren S
    Semin Arthritis Rheum; 2020 Aug; 50(4):636-642. PubMed ID: 32502728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone.
    Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A
    Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable Responses to Tocilizumab in Four Patients with Schnitzler Syndrome.
    Claus J; Vanderschueren S
    J Clin Immunol; 2019 May; 39(4):370-372. PubMed ID: 31111419
    [No Abstract]   [Full Text] [Related]  

  • 6. Refractory serum immunoglobulin M elevation during anti-interleukin (IL)-1- or IL-6-targeted treatment in four patients with Schnitzler syndrome.
    Takimoto-Ito R; Kambe N; Kogame T; Otsuka A; Nomura T; Izawa K; Tabuchi Y; Yoshifuji H; Takeuchi Y; Kabashima K
    J Dermatol; 2021 Nov; 48(11):1789-1792. PubMed ID: 34435697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab as a potential treatment in Schnitzler syndrome.
    Kluger N; Bessis D; Guillot B
    Med Hypotheses; 2009 Apr; 72(4):479-80. PubMed ID: 19150755
    [No Abstract]   [Full Text] [Related]  

  • 8. Remission of Schnitzler syndrome after treatment with anakinra.
    Frischmeyer-Guerrerio PA; Rachamalla R; Saini SS
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):617-9. PubMed ID: 18592830
    [No Abstract]   [Full Text] [Related]  

  • 9. [Schnitzler's syndrome: a case report and literature review of the response to treatment with anakinra].
    Benítez Gutiérrez L; Mellor Pita S; Tutor de Ureta P; Yebra Bango M
    Med Clin (Barc); 2013 May; 140(9):427-8. PubMed ID: 23177777
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous remission of Schnitzler syndrome.
    Asli B; Brouet JC; Fermand JP
    Ann Allergy Asthma Immunol; 2011 Jul; 107(1):87-8. PubMed ID: 21704892
    [No Abstract]   [Full Text] [Related]  

  • 11. Canakinumab in Schnitzler syndrome.
    Vanderschueren S; Knockaert D
    Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.
    Krause K; Bonnekoh H; Ellrich A; Tsianakas A; Wagner N; Fischer J; Maurer M
    J Allergy Clin Immunol; 2020 Jun; 145(6):1681-1686.e5. PubMed ID: 31940469
    [No Abstract]   [Full Text] [Related]  

  • 13. Elevated interleukin-18 secretion from monoclonal IgM+ B cells in a patient with Schnitzler syndrome.
    Bhattacharyya J; Mihara K; Morimoto K; Takihara Y; Hide M
    J Am Acad Dermatol; 2012 Sep; 67(3):e118-20. PubMed ID: 22890741
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on: Schnitzlers syndrome--exacerbation after anti-TNF treatment.
    de Koning HD; van der Meer JW; Simon A
    Rheumatology (Oxford); 2007 Nov; 46(11):1741 author reply 1741. PubMed ID: 17956920
    [No Abstract]   [Full Text] [Related]  

  • 15. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome.
    Volz T; Wölbing F; Fischer J; Braun M; Maggoschitz I; Schaller M; Berneburg M; Biedermann T
    Acta Derm Venereol; 2012 Jul; 92(4):393-4. PubMed ID: 22334118
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.
    Ryan JG; de Koning HD; Beck LA; Booty MG; Kastner DL; Simon A
    J Allergy Clin Immunol; 2008 Jan; 121(1):260-2. PubMed ID: 17936890
    [No Abstract]   [Full Text] [Related]  

  • 17. Schnitzler syndrome with IgG gammopathy and elevated IL-1β and IL-17 in skin biopsy.
    Villarreal RS; VandenBoom T; Gonzalez-Gonzalez FJ; Carter RG; Peters NT; Peters AT; Chiarella SE
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):99-101. PubMed ID: 29162318
    [No Abstract]   [Full Text] [Related]  

  • 18. Schnitzler syndrome: treatment failure to rituximab but response to anakinra.
    Eiling E; Möller M; Kreiselmaier I; Brasch J; Schwarz T
    J Am Acad Dermatol; 2007 Aug; 57(2):361-4. PubMed ID: 17467852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature.
    Gran JT; Midtvedt Ø; Haug S; Aukrust P
    Scand J Rheumatol; 2011 Jan; 40(1):74-9. PubMed ID: 20936987
    [No Abstract]   [Full Text] [Related]  

  • 20. Schnitzler syndrome: chronic urticaria, fever and immunoglobulin M monoclonal gammopathy.
    Shibolet O; Schatz O; Krieger M; Maly A; Caraco Y
    Isr Med Assoc J; 2002 Jun; 4(6):466-7. PubMed ID: 12073428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.